Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.44 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.44 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | CDK9 | P50750 | 2/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059201 | 0.88 | LCK (0.41) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL20839036 | 0.84 | LCK (0.46) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL14059552 | 0.83 | LRRK2 (0.62) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL19384268 | 0.81 | LCK (0.44) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL4606247 | 0.78 | LRRK2 (0.44) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL14058931 | 0.77 | LCK (0.67) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL4930365 | 0.75 | LRRK2 (0.47) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL14059043 | 0.75 | LRRK2 (0.68) | LRRK2 | |
| SCHEMBL4606841 | 0.75 | LRRK2 (0.41) | LCKMAP2K3MAP2K6BTKMAP3K19 | |
| SCHEMBL2479384 | 0.74 | LMNA (0.42) | PARP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2015-10-08 | — | — | US | disclosed |
| CN-103917525-A | Inhibitors of LRRK2 kinase activity | ELAN PHARM INC | 2014-07-09 | — | — | CN | disclosed |
| EP-2726465-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | Elan Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | disclosed |
| WO-2012162254-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | ELAN PHARMACEUTICALS, INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | LCK 4551/4885MAP2K3 2385/4885MAP2K6 2792/4885 |
| US-20150284337-A1 | INHIBITORS OF LRRK2 KINASE ACTIVITY | LRRK2, PARK7, PINK1 | LCK 472/4885MAP2K3 306/4885MAP2K6 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.